Scriptaid is a histone deacetylase inhibitor that has previously been used as a treatment for breast cancer. As a breast cancer treatment, Scriptaid was found to reduce tumors and restore hormonal responsiveness.
A recent clinical study of Scriptaid in a model of moderate traumatic brain injury found that it decreased lesion size and reduced motor and cognitive deficits. The effects on motor and cognitive deficits were long-lasting, with improvements lasting up to 35 days after treatment. Administration was tested both 30 minutes after and 12 hours after injury, both with a similar recovery response.
Researchers suggest that Scriptaid works to protect neurons especially in the hippocampus and parts of the cortex of the brain, and may therefore be a good future candidate for traumatic brain injury treatment.
Wang G, Jiang X, Pu H, et al. Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway: Scriptaid protects against TBI via AKT. Neurotherapeutics. (December 2012).